MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid.
about
Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRIDoes the Reporting Quality of Diagnostic Test Accuracy Studies, as Defined by STARD 2015, Affect Citation?Molecular imaging: from bench to clinic.18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.Added value of arterial enhancement fraction color maps for the characterization of small hepatic low-attenuating lesions in patients with colorectal cancer.Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis.Systemic treatment in breast cancer: a primer for radiologistsPreoperative staging of gallbladder carcinoma using biliary MR imaging.Navigated three-dimensional T1-weighted gradient-echo sequence for gadoxetic acid liver magnetic resonance imaging in patients with limited breath-holding capacity.Differentiation of lipid poor angiomyolipoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.An overview of imaging techniques for liver metastases management.Whole-body PET/MRI for colorectal cancer staging: Is it the way forward?The role of imaging in the surveillance and diagnosis of hepatocellular cancer.Selection and Reporting of Statistical Methods to Assess Reliability of a Diagnostic Test: Conformity to Recommended Methods in a Peer-Reviewed Journal.Cost-effective imaging for resectability of liver lesions in colorectal cancer: an economic decision model.Evaluation of Transient Motion During Gadoxetic Acid-Enhanced Multiphasic Liver Magnetic Resonance Imaging Using Free-Breathing Golden-Angle Radial Sparse Parallel Magnetic Resonance Imaging.
P2860
Q27028207-34AA75C7-2C1A-4800-BAE9-8EDD79C119DDQ30375399-0CCED416-B6E6-4C82-9B59-F88D123B962DQ30420478-1DB6C229-16B7-4EF5-82C5-658391AFF8E8Q33880479-0099A801-3381-4974-9963-9E754E5F9F4AQ35112515-AFC25324-1E3E-46F6-8EBB-2E5F1612993AQ36147405-94A8B269-B90F-4EC0-9297-A78109E1D996Q36510679-13D85782-4C15-4210-B005-6A8AFE04CB56Q38182536-C56232AD-F445-4174-BBF4-E584F9E71350Q38238929-FF18992D-DFEB-41B4-86BB-678FAA4CB814Q38250907-5AB95497-173A-4C4E-BC80-9C97175FA678Q38594431-8C76630E-EDA5-4D98-9CF9-0FDD0DA182B2Q38877730-A3857593-A28C-4559-A3EF-BE78916B831DQ39040960-A336CB0A-A687-44B3-8349-06D33FF7B1F8Q42702576-AC69BA07-8706-44F1-86E2-97B893CEEF39Q47660165-81A20ED4-C2EE-4792-9B5F-647BAE0A1D8FQ47774486-8287C914-2EBE-49C3-B60E-F794A3BA4110
P2860
MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
MR imaging in patients with su ...... contrast agent gadoxetic acid.
@en
MR imaging in patients with su ...... contrast agent gadoxetic acid.
@nl
type
label
MR imaging in patients with su ...... contrast agent gadoxetic acid.
@en
MR imaging in patients with su ...... contrast agent gadoxetic acid.
@nl
prefLabel
MR imaging in patients with su ...... contrast agent gadoxetic acid.
@en
MR imaging in patients with su ...... contrast agent gadoxetic acid.
@nl
P2093
P2860
P1476
MR imaging in patients with su ...... contrast agent gadoxetic acid.
@en
P2093
Byung Ihn Choi
Hee Sun Park
Jeong-Hee Yoon
Ji Hoon Park
Jung Hoon Kim
Kyung Hee Lee
P2860
P304
P356
10.3348/KJR.2013.14.6.894
P577
2013-11-05T00:00:00Z